PitchBook labeled KemNet 'out of business' on its 2026 company profile, which conflicts with other sources that describe the company as active.
SourceKemNet supplies reformulated drugs for specific groups of patients.
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
KemNet is an Edmonton-based B2B healthcare/pharmacy software company founded in 2022 that helps pharmacies order compounded/reformulated medications, with a strong focus on drug-shortage response, regulatory audit trails, and patient-centered custom formulations.
Primary product
B2B platform for ordering compounded/reformulated medications and managing drug-shortage fulfillment for pharmacies
Founded
2022
Headquarters
Edmonton, Alberta, Canada
Team size
1-10 employees
Industry
Software Development
Sub-industry
Healthcare technology / pharmacy software
Offices
0 jobs at KemNet
Check back later for new openings
Business model
Stage
pre-seed
Total raised
$625K
Latest round
Pre Seed · Aug 2022
Latest amount
$500K
Aug 2022 · Y Combinator
Mar 2022
Jan 2022
Leadership
Chief Executive Officer & Founder
Founders
CEO and Founder
Investors
Mission-driven and patient-centered, with recurring messaging around empathy, responsible partnerships, compliance, and solving medicine access problems.
Pricing
B2B marketplace; pricing not publicly disclosed
Differentiators
Customers
Estimated revenue
≈$880K ARR
PitchBook labeled KemNet 'out of business' on its 2026 company profile, which conflicts with other sources that describe the company as active.
SourceEdmonton Sun · Dec 2023
Covers Kemet Group's Times Square billboard campaign and states KemNet is its online platform for customized/reformulated medication requests, with U.S. expansion plans.
Edmonton Journal · Mar 2023
Explains how KemNet began in February 2022 to respond to drug shortages, connects pharmacies with compounding labs, and expanded to additional product categories and overseas ambitions.
Taproot Edmonton · Sep 2022
Profiles KemNet as a B2B platform for reformulated medications and notes early traction with Alberta pharmacies and compounders, plus Y Combinator participation.